159 related articles for article (PubMed ID: 27130167)
1. Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Thorn JC; Turner EL; Hounsome L; Walsh E; Down L; Verne J; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM;
BMJ Open; 2016 Apr; 6(4):e011063. PubMed ID: 27130167
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Hospital Episode Statistics Outpatient Dataset in England.
Thorn JC; Turner E; Hounsome L; Walsh E; Donovan JL; Verne J; Neal DE; Hamdy FC; Martin RM; Noble SM
Pharmacoeconomics; 2016 Feb; 34(2):161-8. PubMed ID: 26386702
[TBL] [Abstract][Full Text] [Related]
3. Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Thorn JC; Turner EL; Walsh EI; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM
BMC Health Serv Res; 2023 Jun; 23(1):610. PubMed ID: 37296430
[TBL] [Abstract][Full Text] [Related]
4. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).
Williams NJ; Hill EM; Ng SY; Martin RM; Metcalfe C; Donovan JL; Evans S; Hughes LJ; Davies CF; Hamdy FC; Neal DE; Turner EL;
BMC Med Res Methodol; 2015 Jan; 15():6. PubMed ID: 25613468
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Keeney E; Sanghera S; Martin RM; Gulati R; Wiklund F; Walsh EI; Donovan JL; Hamdy F; Neal DE; Lane JA; Turner EL; Thom H; Clements MS
Pharmacoeconomics; 2022 Dec; 40(12):1207-1220. PubMed ID: 36201131
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
[TBL] [Abstract][Full Text] [Related]
9. Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.
Lewis AL; Young GJ; Selman LE; Rice C; Clement C; Ochieng CA; Abrams P; Blair PS; Chapple C; Glazener CM; Horwood J; McGrath JS; Noble S; Taylor GT; Lane JA; Drake MJ
Health Technol Assess; 2020 Sep; 24(42):1-122. PubMed ID: 32902375
[TBL] [Abstract][Full Text] [Related]
10. In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial).
Reed SD; Li Y; Dunlap ME; Kraus WE; Samsa GP; Schulman KA; Zile MR; Whellan DJ
Am J Cardiol; 2012 Oct; 110(8):1150-5. PubMed ID: 22762718
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers.
Bajwah S; Oluyase AO; Yi D; Gao W; Evans CJ; Grande G; Todd C; Costantini M; Murtagh FE; Higginson IJ
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012780. PubMed ID: 32996586
[TBL] [Abstract][Full Text] [Related]
13. Evaluating mental health decision units in acute care pathways (DECISION): a quasi-experimental, qualitative and health economic evaluation.
Gillard S; Anderson K; Clarke G; Crowe C; Goldsmith L; Jarman H; Johnson S; Lomani J; McDaid D; Pariza P; Park AL; Smith J; Turner K; Yoeli H
Health Soc Care Deliv Res; 2023 Dec; 11(25):1-221. PubMed ID: 38149657
[TBL] [Abstract][Full Text] [Related]
14. How much does a diabetes out-patient appointment actually cost? An argument for PLICS.
Grant P
J Health Organ Manag; 2015; 29(2):154-69. PubMed ID: 25800330
[TBL] [Abstract][Full Text] [Related]
15. Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
Golan R; Bernstein AN; Gu X; Dinerman BF; Sedrakyan A; Hu JC
Cancer; 2018 May; 124(10):2212-2219. PubMed ID: 29579318
[TBL] [Abstract][Full Text] [Related]
16. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
[TBL] [Abstract][Full Text] [Related]
17. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.
Hall PS; Hamilton P; Hulme CT; Meads DM; Jones H; Newsham A; Marti J; Smith AF; Mason H; Velikova G; Ashley L; Wright P
Br J Cancer; 2015 Mar; 112(5):948-56. PubMed ID: 25602964
[TBL] [Abstract][Full Text] [Related]
18. The cost of the district hospital: a case study in Malawi.
Mills AJ; Kapalamula J; Chisimbi S
Bull World Health Organ; 1993; 71(3-4):329-39. PubMed ID: 8324852
[TBL] [Abstract][Full Text] [Related]
19. What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.
Czoski-Murray C; Lloyd Jones M; McCabe C; Claxton K; Oluboyede Y; Roberts J; Nicholl JP; Rees A; Reilly CS; Young D; Fleming T
Health Technol Assess; 2012 Dec; 16(50):i-xvi, 1-159. PubMed ID: 23302507
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.
Grant A; Wileman S; Ramsay C; Bojke L; Epstein D; Sculpher M; Macran S; Kilonzo M; Vale L; Francis J; Mowat A; Krukowski Z; Heading R; Thursz M; Russell I; Campbell M;
Health Technol Assess; 2008 Sep; 12(31):1-181, iii-iv. PubMed ID: 18796263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
